HOME >> MEDICINE >> NEWS
Estrogen has antitumor activity in hormone therapy-resistant breast tumors

A pair of studies in the November 5 issue of the Journal of the National Cancer Institute suggest that low levels of estrogen--the same hormone that promotes breast cancer in its early stages--can shrink breast tumors that have developed resistance to the drugs tamoxifen and raloxifene.

Tamoxifen is a selective estrogen receptor modulator (SERM) used to treat estrogen receptor-positive breast cancers and prevent recurrence of the disease. However, tamoxifen often loses effectiveness over time and can subsequently stimulate breast cancer growth. New endocrine therapies, such as aromatase inhibitors and the antiestrogen fulvestrant, are being are used to augment the effects of tamoxifen, although some studies are suggesting that low levels of estrogen may also inhibit the growth of tamoxifen-stimulated breast tumors.

Clodia Osipo, Ph.D., and V. Craig Jordan, Ph.D., D.Sc., of the Robert H. Lurie Comprehensive Cancer Center at Northwestern University in Chicago, and their colleagues examined the effect of tamoxifen, the estrogen estradiol, and fulvestrant, both alone and in various combinations, in a mouse model of tamoxifen-stimulated human breast cancer.

The researchers found that low levels of estradiol caused tamoxifen-resistant breast tumors to regress, apparently by increasing apoptosis (cell suicide) through decreased expression of Her2/neu and NF-κB, two factors that inhibit apoptosis, and increased expression of the death receptor protein Fas, which regulates apoptosis.

Combined treatment with fulvestrant plus estradiol unexpectedly promoted the growth of tamoxifen-stimulated breast tumors, suggesting that the use of fulvestrant in patients with sufficient levels of circulating estrogen may actually stimulate tumor growth.

In the second study, Hong Liu, M.D., Ph.D., of the Robert H. Lurie Comprehensive Cancer Center, Jordan, and their colleagues examined whether low doses of estradiol would also have an
'"/>

Contact: Linda Wang
jncimedia@oupjournals.org
301-841-1287
Journal of the National Cancer Institute
31-Dec-2000


Page: 1 2

Related medicine news :

1. Estrogen-associated COX-2 pathways explain protection from heart disease in female mice
2. Estrogen or stimulating environment boost memory
3. Estrogenlike drugs may eventually help postmenopausal women with weight gain
4. Estrogen offers no overall benefit for disease prevention in postmenopausal women with hysterectomy
5. Estrogen makes the brain more vulnerable to stress
6. Estrogen replacement increases risk factors for arrhythmia and sudden death
7. Estrogen may lower womens risk of heart disease by working as damper on inflammation
8. Estrogen may dictate what problem-solving strategy brain uses
9. Testosterone may reduce risk of stroke in men; Estrogen levels not related to stroke
10. Estrogens role in preventing female cardiac disease
11. Estrogen shows potential as stroke treatment, UF animal studies show

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:11/14/2018)... ... November 14, 2018 , ... ... the All-In-One Video Ecommerce Solution, to power its "Ask an Expert" online mentor ... in live 30 and 60-minute one-to-one virtual sessions that are focused on starting ...
(Date:11/14/2018)... ... November 14, 2018 , ... For what is a first time at ... for Eating Disorders, will present an overview of the EFFT model with a focus ... at the 2019 event. , Next year’s 33rd iaedp™ Symposium is slated for ...
(Date:11/14/2018)... Ind. (PRWEB) , ... November 14, 2018 , ... ... 25mm lengths to its FortiCore® rotatable Posterior Lumbar Interbody Fusion (PLIF) devices. , ... driven growth with the expansion of their FortiCore PLIF product line with the addition ...
(Date:11/13/2018)... ... 13, 2018 , ... A survey by the publishers of ADC Review ... antibody therapies reached U.S. $ 4 billion. Approximately forty-five percent of this market included ... therapies (including ADCs) is expected to grow significantly, to U.S. $ 17 billion by ...
(Date:11/13/2018)... CLAREMONT, Calif. (PRWEB) , ... November 13, 2018 ... ... Surgeon General called for increased awareness and use of naloxone, an opioid overdose ... trained pharmacists to provide naloxone to individuals without a prescription. , ...
Breaking Medicine News(10 mins):
(Date:11/15/2018)... ... November 15, 2018 , ... ... healthcare organizations, today announced a strategic partnership with Formativ Health, a technology-enabled, ... Connector will perform platform integrations that connect Formativ Health’s clients’ Healthcare IT ...
(Date:11/15/2018)... ... November 15, 2018 , ... Mobile exoskeleton ... estimated to continue its dominance during the study period. The segment growth is ... to the wearer while augmenting strength to lift heavy load. Stationary products are ...
(Date:11/15/2018)... ... November 15, 2018 , ... This exclusive ranking ... moving our economy forward. The award, known as the Omni500, represents the most ... of sustainable growth among the communities they serve.2018 marks OMNIKAL’S 18th annual listing ...
Breaking Medicine Technology:
Cached News: